Despite its relatively low profile since it kicked off its third phase last spring, the Broad Institute's RNAi Consortium is proceeding apace, although its mission has expanded beyond its initial focus of just RNAi.
The publication comes as the RNAi Consortium looks to expand its work beyond gene silencing to include gain-of-function research.
While the exact goals of the so-called TRC3 have yet to be defined, the initiative expects that these will include the expansion of its scope to include reagents targeting non-coding RNAs.
The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.
Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.
In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.
Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.